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INTRODUCTION 
 
 
Hereditary ataxias 
 
Hereditary cerebellar ataxias are a group of neurodegenerative diseases with 
clinical and genetic heterogeneity and variable age at onset. They usually present 
with incoordination of movement, unsteadiness, hypotonia, dysarthria, and/or 
oculomotor disorder due to cerebellar dysfunction. Additional neurological 
(peripheral neuropathy, pyramidal tract dysfunction, extrapyramidal signs, 
oculomotor abnormalities, intellectual disability, cognitive impairment, epilepsy, 
optic atrophy) or extraneurological signs (endocrine dysfunctions, 
cardiomyopathy, cataract) often complete the clinical picture. 
For a long time the most important classification of ataxias consisted of Anita 
Harding classification who divided degenerative cerebellar ataxias in two groups: 
the early onset forms, mainly characterized by an autosomal recessive 
transmission, and the late onset ataxias with autosomal dominant inheritance. 
From the detection in 1993 of the CAG triplet repeat expansion in ATXN1 gene, 
associated with Spinocerebellar ataxia type 1 (SCA1) (Orr et al., 1993), and in 
1996 of the GAA expansion of FXN gene in Friedreich ataxia (Campuzano et al., 
1996), advances in molecular genetics allowed the discovering of several new 
genes causing cerebellar and spinal ataxias, showing the limits of the old 
classification. 
A pathogenic approach to classify hereditary ataxias did not consider genetic or 
natural history-base criteria, and divided the disorders into five main categories: 
1) mitochondrial; 2) metabolic; 3) defective DNA repair; 4) abnormal protein 
folding and degradation; 5) channelopathies (De Michele et al, 2004). 
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Gradually, the old approach of linkage analyses in informative families, positional 
cloning and candidate gene testing were replaced or complemented by Next 
Generation Sequencing (NGS), and since 2010 an increasing number of new 
genes were associated to ataxias, and clinical phenotypes of old genes has been 
expanded. 
Genetically, all transmission modes have been described, and diagnostic work-up 
remains a challenge. In autosomal dominant ataxias, referred to as spinocerebellar 
ataxias (SCA) in genetic nomenclature, at least 36 genes have currently been 
described, but in over 40% of cases the genetic cause remains unknown (Durr et 
al., 2010; Bird, 1998). Even more intricate is the genetic picture of autosomal 
recessive ataxias, with 45 genes in which ataxia is the core presenting feature, 22 
genes in complex or multisystem recessive disorders that have prominent ataxia, 
and at least 12 genes associated with recessive disorders that may occasionally 
present with ataxia as secondary feature (Beaudin et al., 2017). The most common 
form is Friedreich ataxia, caused by GAA expansion, but numerous genes are 
involved in complex syndromes (Anheim et al., 2012). X-linked inheritance 
suggests consideration of the fragile X–associated tremor–ataxia syndrome or 
adrenomyeloneuropathy. 
This wide genetic heterogeneity makes the molecular diagnosis of hereditary 
ataxias extremely difficult and economically costly, so many ataxic patients 
remain "orphans" of molecular diagnosis. 
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Next-generation sequencing: single-gene, gene panel, or 
exome/genome sequencing 
The use of Sanger sequencing strategies for clinical investigation has become 
obsolete due to its time- and money-expensive features. In the past few years, 
Next-Generation Sequencing (NGS) has allowed to sequencing a large number of 
genes with increasing accuracy, speed and throughput of sequencing reducing also 
costs. NGS technology has revolutionized the paradigm of clinical diagnostics, 
helping to end the long search for a genetic cause often referred as “diagnostic 
odyssey” (Johnson, 2015), bringing an extremely wide application of NGS in 
biomedical domain (Figure 1). At the same time costs for genome sequencing 
dropped precipitously (Figure 2) and it is possible that in few years low-pass 
genome investigation will be a feasible option in clinical settings (Hayden 2014). 
Anyway, even if exome sequencing techniques are probably going to become the 
“gold standard” in mendelian diseases, to date multi-gene panels still represent an 
optimal time- and cost-effective first tier screening approach in rare disorders. 
Four different molecular tests are currently available: Traditional Sanger Single- 
Gene Test, gold standard for sequencing, which is commonly used for 
investigation of disease-causing specific gene; Targeted Resequencing Panels 
(TRP), which consists in the analysis of the coding exons of a restricted number  
of genes; Exome Sequencing (ES) which includes the sequencing of the coding 
1% of the entire human DNA, where lies up on the 85% of all pathogenic 
mutations; Whole Genome Sequencing (WGS), the most expensive, all-inclusive 
technique, detecting mutations in coding and non-coding regions and also copy 
number variations (CNV) (Hui, 2014; Xue et al., 2015). Single-gene test is 
preferred when distinctive clinical findings clearly point to a specific gene, 
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characterized by minimal locus heterogeneity. Single-gene test imply no 
incidental findings and a minimal number of variants of unknown significance 
(VOUS). VOUS is considered if the variant has never been reported in any of the 
databases for the assessment of variants’ pathogenicity, and is not the kind with 
clear pathogenicity (i.e., frameshift, stop codon, or splice-site mutations). 
TRP are the most cost-effective application, offering the possibility to make a 
differential diagnosis in disorders with overlapping phenotype and genetic 
heterogeneity, but well-defined disease-associated genes. Technical procedure of 
TRP needs Sanger confirmation and complementary assays to detect 
deletions/duplications. The overall coverage is higher than ES, VOUS are less 
found, and is less likely to incur in incidental findings than ES. 
ES and WGS show success most often in cases with extreme clinical 
heterogeneity and nonspecific neurological disorder or in detection of de novo 
mutations (Yang et a., 2013). These latest methods have allowed the recognition 
of many novel genes not currently associated with diseases, and the connection of 
novel phenotypes with previously described genes. This fascinating role of ES and 
WGS is however burdened by the difficulty of discriminating, amongst the many 
non-disease causing variants identified, the true mutations. An accurate 
phenotyping of the patients is a prerequisite for the interpretation of the variants. 
Another challenge when performing vast scale sequencing such as ES or WGS is 
potential detection of incidental findings, defined as genetic variants with medical 
or social implications that are discovered during genetic testing for an unrelated 
indication (Wolf et al., 2012). The rate of reportable incidental findings can range 
from 1 to 8.8%, depending on sequencing quality, variant selection, subject
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cohort, and whether the laboratory is using the gene list recommended by the 
American College of Medical Genetics (ACGM) and Genomics Working Group 
(Berg et al., 2013; Lawrence et al., 2014). The ACMG subsequently established 
the Secondary Findings Maintenance Working Group to develop a process for 
curating and updating the list of high risk genes, supporting the reporting of 
known or expected pathogenic variants, excluding VOUS (Kalia et al., 2017). 
 
 
Next-generation sequencing in ataxias 
 
Routine procedure for testing hereditary ataxias generally include analysis for 
CAG expansions in autosomal dominant forms (SCA1, SCA2, SCA3, SCA6, 
SCA7, SCA17, DRPLA) and for the GAA intronic expansion in FXN gene 
associated with Friedreich ataxia, reaching a molecular diagnosis in about 40% of 
recessive cases and about 50% of dominant ones (Anheim et al., 2010; Durr, 
2010). The repeat expansions can be easily and cheaply tested using standard PCR 
methods. Few other genes are commonly screened by Sanger sequencing because 
of prohibitive costs or limited gene test availability. So, the advent of NGS 
promised to revolutionize genetic testing and potentially could be part of standard 
evaluation of patients. 
From 2013 to date, at least twelve NGS studies have investigated genetic etiology 
of large cohorts of ataxic patients, five using TRP (Nemeth et al, 2013; Mallaret et 
al., 2016; Hadjivassiliou et al., 2017; Coutelier et al., 2017; Iqbal et al., 2017) and 
seven ES approaches (Ohba et al., 2013; Sawyer at al., 2014; Fogel et al., 2014; 
Pyle et al., 2015; Keogh et al., 2015; van de Warrenburg et al., 2016; Marelli et al, 
2016). 
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Targeted Resequencing Panels in ataxias: diagnostic yield and detected genes 
 
 Nemeth et al. studied by TRP 50 ataxic patients with a positive family history or 
an age at onset below 50 years (Nemeth et al., 2013). The panel included a total of 
58 genes known to be associated with human ataxia and additional 59 candidate 
genes derived from functional data or animal models. Clearly pathogenic 
mutations were found in nine cases with a detection rate of 18%. The most likely 
predictors of detecting a mutation were an adolescent age of onset (present in 8/9 
positive cases), a family history, a complex and progressive phenotype. 
Pathogenic mutations were detected in SETX gene, the gene causative of Ataxia 
Oculomotor Apraxia 2 (AOA2), in two patients. This diagnosis was not 
previously been made, despite the suggestive clinical features and the presence of 
elevated levels of the biomarkers alfafetoprotein, because of lack of availability of 
genetic testing in UK. The other genes detected, in single cases, were SACS gene 
(responsible of ARSACS, Autosomal Recessive Spastic Ataxia of Charlevoix- 
Saguenay), MRE11A gene associated with Ataxia-Teleangectasia-like Disorder, 
SCA11, SCA13, SCA14, SPARCA1 and DARS2. The last gene is responsible of 
autosomal recessive Leukoencephalopathy with Brainstem and Spinal cord 
involvement and Lactate elevation (LBSL). In the index case only one mutation 
has been found, but clinical phenotype was very consistent, so diagnosis was 
considered evident. 
 145 unrelated patients with autosomal recessive or sporadic progressive cerebellar 
ataxia and age at onset before 60 years were analyzed by TRP included 57 ataxia 
genes (Mallaret et al., 2016). A molecular diagnosis was made in 27/145 patients
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(19%). Genetic analysis identiﬁed two pathogenic mutations in ANO10 (six 
patients), in SETX (four patients), in SYNE1 and ADCK3 (three each), in SACS 
and APTX (two each) and in TTPA, CYP27A1, POLG (one each). 
 From June 2014 to September 2016 at the Shefﬁeld Ataxia Centre of UK 146 
ataxic patients have been tested with a TRP including 42 ataxia genes 
(Hadjivassiliou et al., 2017). Of these, 54 patients had autosomal dominant family 
history and 17 a family history consistent with autosomal recessive inheritance. 
Confirmed pathogenic mutations were found in 35 cases with a diagnostic yield of 
24%. VOUS were detected in eleven cases. Positive results were obtained in 46% 
of patients with autosomal dominant inheritance, in 24% of patients with a family 
history consistent with recessive inheritance, and in 27% of patients with sporadic 
ataxia. More frequent genetic diagnosis included Episodic Ataxia type 2 (EA2, 
CACNA1A gene) recognized in eleven cases, SCA14 in five cases, SCA5 and 
Spastic Paraplegia 7 (SPG7) in four patients each, ARSACS and SCA35 in three 
patients each. 
 After exclusion of CAG expansions in SCA genes, 412 index cases with 
dominantly inherited cerebellar ataxia, from SPATAX (The Network of hereditary 
forms of SPAstic paraplegias and cerebellar ATAXias) cohort, underwent a 65 
genes TRP and TaqMan PCR assay for deletions in ITPR1 gene, responsible for 
SCA15 (Coutelier et al., 2017). Relevant genetic variants were identified from 
panel sequencing in 12% of patients, including confirmed pathogenic variants and 
probably/possible variants. With the combined approach of panel sequencing and 
TaqMan PCR assay, the diagnostic yield reached 14%, as deletions in ITPR1 gene 
were detected in eleven patients. 89 VOUS were identified. Apart from 
diagnosing SCA15, the most frequently mutated gene was CACNA1A in 16
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unrelated patients. Next in frequency were SPG7 biallelic variants (in nine 
patients), monoallelic AFG3L2 mutations responsible of SCA28 (in seven 
patients), and monoallelic KCND3 mutations in three cases associated with 
SCA19/22. 
 Recently, Iqbal et al. described the results of a study of 105 index cases with 
hereditary cerebellar ataxia or spastic paraplegia, analyzed by a gene panel 
targeting 159 neurodegenerative disorders genes, including 91 genes implicated in 
classical hereditary ataxias and spastic paraplegias (Iqbal et al., 2017). About the 
results of the 58 ataxic patients, eight probands carried pathogenic or likely- 
pathogenic variants, with detection rate of 14%. VOUS were detected in eight 
cases. Definite molecular diagnosis have been detected in ARSACS, SCA5, 
SCA14, SCA15, SCA19/22, SCA28, SCA35, and EA2. 
 
 
Exome Sequencing in ataxias: diagnostic yield and detected genes 
 
 Ohba et al. performed a family-based ES in 23 index cases with cerebellar atrophy 
in childhood on brain MRI (Ohba et al., 2013). They found three cases with de 
novo mutations in CACNA1A (two each) and ITPR1 genes, and six cases with 
compound heterozygous mutations in FOLR1 (Neurodegeneration from cerebral 
folate transport deficiency), C5orf42 (Joubert syndrome), POLG, TPP1 (SCAR7) 
and PEX16 (Zellweger syndrome), reaching a diagnostic yield of 39%. 
 Pediatric-onset cerebellar ataxia was investigated within a Canadian project to 
identify novel genes for rare childhood disorders using ES. Analysis of the 28 
families included in the study resulted in a molecular diagnosis for eleven families 
in a known disease gene (ARSACS, AOA2, Holmes syndrome related to RNF216 
gene, Perrault syndrome, Congenital Disorders of Glycosylation type Ia, 
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Neurodegeneration with Brain Iron Accumulation related to PLA2G6 gene), and two new 
disease genes were identified. The combined molecular diagnosis rate was of 46%. In 
detail, all consanguineous families investigated reached a diagnosis; the diagnostic yield 
for patients born to nonconsanguineous parents with more than one affected child was of 
43%, while for simplex cases of 27% (Sawyer at al., 2014). 
 A clinical ES of 76 ataxic patients, mainly with adult- and sporadic-onset, made a 
definitive genetic diagnosis in 21% of cases and identified probable variants in an 
additional 40% of cases (Fogel et al., 2014). SYNE1 and SPG7 were the most 
frequent genes detected. 
 Pyle et al. performed an ES in 22 probands with suspected inherited ataxia (Pyle 
et al., 2015). Twelve of 22 individuals (54%) had family history, suggestive of 
dominant inheritance in 5/12, and autosomal recessive in 7/12. Confirmed 
pathogenic variants were found in 9/22 probands, with diagnostic yield of 41%. 
Possible pathogenic variants were identified in 5/22 probands and VOUS in two 
cases. Three cases were positive for SACS mutations and two cases for TUBB4A 
gene mutations, responsible for Hypomyelinating Leukodystrophy 6. One case 
was positive for SPG7. 
 Twelve sporadic adult-onset (> 30 years of age) ataxic patients were investigated 
with ES in a UK study (Keogh et al., 2015). In 33% of patients were identified a 
pathogenic mutations (two cases of SPG7, one each of ANO10 and SYNE1 genes) 
and VOUS were found in additional two cases (17%). 
 van de Warrenburg et al. reported the results of a clinical ES performed in 76 
patients with cerebellar ataxia and spastic paraplegia, filtered for a "movement
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disorders" bioinformatic gene panel, including about 200 genes implicated in 
cerebellar ataxias, spastic paraplegia, parkinsonism, choreas and other 
hyperkinetic movement disorders (van de Warrenburg et al., 2016). Of the 28 
ataxic patients nine had causative variants, with a diagnostic yield of 32%. The 
most frequent pathogenic variant were detected in SPG7 gene (three cases). A 
possible causative variant were detected in one additional patient. 
 A strategy of TRP, extended, for negative cases, to a mini-ES, designed for 
genomic analysis of the coding regions of 4813 genes, and coupled to a bio- 
informatic approach for Copy Number Variations detection, was applied to 33 
patients with progressive cerebellar ataxia and onset before the age of 50 (Marelli 
et al., 2016). Confirmed pathogenic variants were found in 14 patients (42%), 
more frequently in cases with positive family history. VOUS were found in eight 
patients (24%). A positive family history, followed by younger age at onset, were 
the most important factors associated with positive results. Disease causing 
mutations were identified in five recessive ataxia genes (SETX, NPC1, ATM, 
HSD17B4, ERCC4) and in three dominant ataxia genes (ATXN2, PRKCG, PDYN), 
with mutations in more than one family for SETX (five probands), NPC1 (two 
probands) and PRKCG genes (two probands). 
 
 
Considering all TRP studies, the average diagnostic rate was 17%. Including 
VOUS as representing relevant genetic information, the diagnostic rate would rise 
ranging between 26% and 34%. The average diagnostic yield of ES studies was 
36%. Including VOUS the value raised to 53% (Figure 3). 
However, the number of patients recruited for TRP analysis is widely larger 
compared to those who underwent ES (an average of 172 and 32 in TRP and ES,
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respectively), suggesting a possible selection bias in ES cohorts and an average 
diagnostic rate quite overestimated than a less selected cohort. Moreover, the 
cohorts of the different studies were, for the most part, not naïve and largely 
nonconsecutive. Most patients, in fact, have already been variably screened for 
several genes, although possible is the lacking of systematicity in which genes 
were excluded before NGS. Moreover, the diagnostic power of a TRP depends 
heavily on the number of the genes included in the test panel, and if these genes 
are the right genes. A multi-gene panel is usually preferred considering the 
relatively higher deep coverage. ES has the power to identify causal variants also 
in newly described disease genes, or in extremely rare disease genes not present in 
targeted capture assay, discovering new genes and broadening the phenotype. 
Even if ES can bypass the selection a set of candidate genes, the interpretation of 
the huge amount of data depends to a focused and efficient assessment of the 
patient. The collaboration between the laboratory researchers and the clinicians is 
therefore of primary importance. 
In the twelve NGS studies analyzed, an overall of 53 different genes were 
detected, in both autosomal dominant (35%) and recessive (65%) genes. 
Interestingly, 66% of the variants detected lie in only eleven different genes: 
CACNA1A (Episodic Ataxia type 2 - EA2), SPG7 (Spastic Paraplegia 7), SETX 
(Ataxia Oculomotor Apraxia type 2 - AOA2), SACS (Autosomal Recessive 
Spastic Ataxia of Charlevoix-Saguenay - ARSACS), PRKCG (Spinocerebellar 
Ataxia type 14 - SCA14), AFG3L2 (Spinocerebellar Ataxia type 28 - SCA28), 
ANO10 (Spinocerebellar ataxia Autosomal Recessive 10 - SCAR10), KCND3 
(Spinocerebellar Ataxia type 19 - SCA19), SPTBN2 (heterozygous mutation 
responsible of Spinocerebellar Ataxia type 5 - SCA5; homozygous mutation
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responsible of Spinocerebellar ataxia Autosomal Recessive 14 - SCAR14), SYNE1 
(Spinocerebellar ataxia Autosomal Recessive 8 - SCAR8), and KCNC3 
(Spinocerebellar Ataxia type 13 - SCA13). About 64% mutations have been found 
in genes traditionally known as cause of hereditary ataxias, whereas 30% fall in 
genes recently discovered because of NGS strategies, and only 6% occur in genes 
not typically considered associated with ataxia. This frequency estimates, 
however, could be not reliable because of some genes were not available for 
testing before NGS in some centers, such as SETX gene that is not routinely tested 
in UK and France, or few families have been screened for SYNE1 gene as the gene 
is very large at 146 exons in length. 
 
 
PROJECT AIMS 
 
The aim of our research was to investigate the role of a Targeted Next-Generation 
Resequencing Panel for ataxias in clinical practice, studying a heterogeneous 
group of patients with inherited ataxia who were a diagnostic challenge and are 
representative of the range of cases referred for serial genetic testing. 
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SUBJECTS AND METHODS 
 
 
Inclusion criteria 
 
Thirty-nine index patients were recruited from the Ataxias Clinic of Neuroscience, 
Reproductive and Odontostomatological Science Department of the Federico II 
University. The cohort was largely nonconsecutive. No restriction on age at onset 
or inheritance pattern were made, but there had to be a clinical suspicion of a 
genetic etiology, based on the combination of cerebellar ataxia phenotype plus 
either an onset age below 45 years or a positive family history. Also congenital 
ataxias were included. Most patients had already undergone extensive genetic 
testing, with a mean of 3.6 genes tested. Moreover, mutations in the most likely 
genes had to be excluded. All patients provided written consent for the study. 
 
 
Inherited Ataxias Progression Scale 
 
Progression of the disease was evaluated using the Inherited Ataxias Progression 
Scale (IAPS) (Campanella et al., 1980). 
This scale is composed of four phases: 
 
- Phase I: asymptomatic patient, identified among sibs or sons of a proband; 
 
- Phase II: ataxia but independent; 
 
- Phase III: permanently dependent on walking aids; 
 
- Phase IV: permanently dependent on wheelchair. 
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DNA extraction 
 
DNA samples were obtained from peripheral blood and treated with anticoagulant 
ethylenediaminetetraacetic acid (EDTA). DNA extraction was performed using 
nucleic acid isolation automated system MagNA pure compact (Roche). Genomic 
DNA was then qualitatively tested in 1,5% agarose gel. 
 
 
Preliminary investigations 
 
Prior to undergo TRP, all patients were tested for pathological expansions in 
SCA1, 2, 3, 6, 7, 8, 12, 17 and for the intronic GAA expansion in FXN. 
Pathological CAG expansions in SCA1, 2, 3, 6, 7, 8, 12, 17 have been 
investigated using validated fluorescently-based TP PCR methodologies (Warner 
et al., 1996) (Cagnoli et al., 2006). Capillary electrophoresis was performed with 
3130xl Genetic Analyzer (Applied Biosystems) and fragment analysis was 
performed using software GeneMapper 4.0 (Applied Biosystems). 
Pathological intronic GAA expansion in FXN was tested using a long-PCR 
method (Campuzano et al., 1996). PCR products were tested in 0,8% agarose gel 
and molecular weight analysis was made using Image Lab (Bio-Rad). 
Thermocycler GeneAmp PCR System 9700 (Applied Biosystems) was used in 
both investigation, and also in Sanger sequencing for confirmatory studies and in 
SureSelect Target Enrichment System (Agilent Technologies). 
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Confirmatory studies 
 
Pathological mutations identified with NGS were confirmed by Sanger 
sequencing (Sanger et al., 1977). Amplicons of interest were obtained by PCR and 
amplified products were purified with Exo-SAP (exonuclease I-shrimp alkaline 
phosphatase). Nucleotide sequences were determined performing capillary 
electrophoresis using automated sequencer 3500 Genetic Analyzer (Applied 
Biosystems) in association with BigDye Terminator v3.1 Cycle Sequencing Kits 
(Life Technologies) and G50 Dye terminator removal kit (RBC Bioscience). 
Electropherograms analysis was performed with software SeqScape v2.7 (Life 
Technologies). 
 
 
Ataxia targeted resequencing panel 
 
Gene panel creation 
 
A gene panel containing 273 genes known or supposed to be related to hereditary 
ataxias was created using SureDesign (Agilent Technologies) software (Table 1). 
 
 
Sample library preparation 
 
DNA samples were processed adopting SureSelect Target Enrichment System 
(Agilent Technologies). First, genomic DNA (gDNA) was quantitatively tested 
with Qubit dsDNA Broad Range Assay (Invitrogen). 2 µl of 25 ng/µl genomic 
DNA was hence enzymatically fragmented and adaptors were added to ends of the 
fragments, and furthermore adaptor-tagged gDNA libraries were repaired and 
PCR-amplified (Figure 4, A). Once DNA library amplicons were prepared, 
hybridization with regions of interest was performed using biotinylated RNA 
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probes (Figure 4, B). Streptavidin coated magnetic beads were then used in order 
to capture biotinylated probes bounded to gDNA of interest and to wash out the 
rest (Figure 4, C). Captured target DNA libraries were then amplified using dual 
indexing primers, a truly important process because samples were then 
multiplexed for sequencing, so was necessary to maintain a correspondence 
between each amplicon and its corresponding patient. Since libraries were pooled, 
amplicons were ready to be sequenced. 2200 TapeStation (Agilent Technologies) 
was used to assess DNA quality and quantity (D1000 assay was used for pre- 
hybridization libraries and High Sensitivity D1000 assay for post-hybridization 
libraries). 
 
 
Sequencing 
 
A MiSeq Illumina platform was used for high-throughput sequencing in this study. 
MiSeq Illumina sequencing adopts a “bridge amplification” approach. MiSeq 
reagent kit v2 (2x150bp) and 4.5 Gb flow cell were used in every sequencing. 
First, capture libraries previously prepared from each patient were pooled for 
multiplex sequencing (Figure 5, 1). A variable multiplexed pool concentration 
ranging between 6 pM and 10 pM were used for every sequencing, and 1% PhiX 
(a phage short genome used as sequencing control) was added to the sample pool. 
Hence, DNA was chemically denaturated and sequencing got start. Single- 
stranded fragments randomly bound the surface of the flow cell, a solid support 
where lie immobilized complementary oligonucleotides (Figure 5, 2). Nucleotides 
and enzyme were then added to initiate solid-phase bridge amplification (Figure 5, 
3) and so double-stranded bridges were obtained (Figure 5, 4). Following 
denaturation left single-stranded templates anchored to the substrate (Figure 5, 5) 
and in this way several millions dense clusters of double-stranded DNA were 
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generated in each channel of the flow cell. Since the added nucleotides were 
marked with four different fluorophores, every time a base complementary to a 
single strand was incorporated, a laser excited the molecule and the light signal 
was recorded in order to identify which base had just been added (Figure 6). This 
process occurred at the same time for every strand attached to the flow-cell, and 
leaded to the identification of the nucleotidic sequence of every amplicon. 
 
 
Data analysis 
 
Data analysis was performed using software SureCall (Agilent Technologies) 
which allows to align sequence raw data with reference human genome sequence 
(hg19). Differences between these two inputs represent the variants identified in 
DNA samples used for sequencing. After that, variants found were analyzed using 
Ingenuity variant analysis (Qiagen) and filtered using the following parameters: 
 Call quality: A score which represents the probability that a base call is true. 
 
In this study, variants with QC<30 (corresponding to a base call 
accuracy>99.9%) were discarded. 
 Read depth: Represents how many times a variant has been sequenced. In 
this study, variants with read depth<20 were discarded. 
 Frequency: Only rare variants were considered, so those with population 
frequency higher than 1% were discarded.  
Main database we referred to was  Genome Aggregation Database 
(gnomAD) (http://gnomad.broadinstitute.org), a online database which contains 
frequencies of genetic variants in over 120.000 exome sequences and 15.000 
genome sequences from unrelated individuals. 
 False positives: Some variants may be present in several samples, and is 
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unlikely if we are considering a group of rare disease. Indeed, these are 
often NGS sequencing bias. In order to solve this problem, variants shared 
by 3 samples or more were discarded. 
 
 
Moreover, in order to evaluate the functional impact of protein mutations, 
algorithms SIFT (Sorting Intolerant From Tolerant) (http://sift.jcvi.org) and 
PolyPhen2 (Polymorphism Phenotyping) (http://genetics.bwh.harvard.edu/pph2) 
were used, both predicting the impact of missense mutations using parameters like 
sequence homology and phylogenetic information. 
Splicing variant predictions were also performed using algorithms NetGene2 
(http://genetics.bwh.harvard.edu/pph2) and BDGP (http://www.fruitfly.org) for 
intronic variants downstream and upstream 20 nucleotides from each exon 
considered. Mutations in acceptor and donor splicing site were considered 
pathogenetic. 
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RESULTS 
 
Clinical characteristics of the patients 
 
54% of probands were male. The mean age at disease onset was 28 years 
(standard deviation 15.3; range 1-55 years). Sixteen out of 39 patients (41%) 
presented an onset before the age of 25, four of which patients presented with a 
congenital ataxia. Mean disease duration was 20 years (standard deviation 11.3; 
range 2-46 years). Fifteen out of the 39 patients (38%) had a positive family 
history, with 20% of cases with known consanguineous parents. The majority of 
patients had additional neurological features that included spasticity, peripheral 
neuropathy, cognitive impairment/decline, tremor, hyperkinetic choreiform 
movements, epilepsy, myoclonus, and dystonia, or extraneurological features 
included hypo or hypergonadotropic hypogonadism, skeletal deformities, cataract, 
and hypoacusia. Most patients had already undergone extensive genetic testing, 
with a mean of 3.5 genes. Clinical features and the genetic results are shown in 
table 2, 3 and 4. 
 
 
Genetic Results 
 
High quality sequencing data was obtained with an average of 96% bases covered 
 
>100x and 82% bases covered >200x in the targeted regions (Figure 7). By 
applying our filtering criteria, we identified eighteen probands out of 39 (46%) 
carrying pathogenic variants (Table 2). VOUS were found in nine probands (23%) 
(Table 3). In the remaining twelve out of 39 cases (31%) no candidate variants or 
variants with unlikely pathogenicity were identified (Table 4). 
23 
 
The comparison between the patients with positive diagnostic results and patients 
with VOUS or negative results showed a more frequent positive family history 
(66% vs 38%) in patients with confirmed pathogenic variants. 
 
 
Patients with confirmed pathogenic variants (table 2) 
 
Disease causing mutations were identified in 18 cases (17 recessive ataxias and 
one autosomal dominant). We recognized ten different genes: SPG7 (five 
probands), PNPLA6 (three probands), SYNE1 (two probands), SETX (two 
probands), RNF216, ZFYVE26, ANO10, PMM2, ATP13A2 and TGM6 (one 
proband each). The most frequent cause of ataxia in our cohort was SPG7 (spastic 
paraplegia 7). All of the five cases (PT 1-5) had a prominent ataxic phenotype with 
cerebellar atrophy at brain MRI (Figure 8), but in three of them pyramidal signs were also 
present (PT 2, 3, 4) and in one case associated with ophthalmoparesis (PT 2). However, 
two of the five patients had no pyramidal signs, but rather a pure cerebellar ataxia (PT 1, 
5). Both these patients carried a common variant in SPG7 (p.Ala510Val), one in 
compound heterozygosity, one in homozygosity, confirming that the pure ataxia 
phenotype is not dependent to a specific genetic variant, but it is part of the SPG7 disease 
spectrum (van de Warrenburg et al., 2016). 
Second gene for frequency detected was PNPLA6 (patatin-like phospholipase 
domain-containing protein 6), a gene associated with Gordon Holmes/Boucher- 
Neuhäuser syndrome/ spastic paraplegia 39 (SPG39). The clinical spectrum of 
PNPLA6 mutations unfolds along four different neurological key features: ataxia, 
chorioretinal dystrophy, hypogonadotropic hypogonadism and motor neuron 
disease (upper motor neuron disease with or without additional lower motor
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neuropathy). Gordon Holmes syndrome is classically described as an early-onset 
autosomal recessive cerebellar ataxia with hypogonadotropic hypogonadism 
associated with brisk reﬂexes (Holmes, 1907). Cognitive impairment completes 
the phenotype. In Boucher-Neuhäuser syndrome the ataxia  with 
hypogonadotropic hypogonadism is additionally associated with chorioretinal 
dystrophy (Boucher and Gibberd, 1969; Neuhauser and Opitz, 1975). In SPG39 
spastic paraplegia is associated with distal upper and lower extremity wasting. 
In 2013-2014 three different NGS studies recognized three genes associated with 
ataxia and hypogonadotropic hypogonadism: RNF216 either alone or in 
combination (digenic mutations) with mutations in OTUD4 (Margolin et al., 
2013), STUB1 (Shi et al., 2014), and PNPLA6 (Synofzik et al., 2014). 
Two of the three probands (PT 6 and 7) here detected presented with a classical 
phenotype, and sexual hormones assessment revealed a hypogonadotropic 
hypogonadism (Table 5). Brain MRI showed cerebellar atrophy (Figure 9).  In 
both patients visual assessment showed a chorioretinal dystrophy, with visual 
acuity of 7/10 in both eyes for PT 6 and of 1/120 and 1/50 in PT 7. Cognitive 
evaluation revealed in both patients a mild intellectual disability. The third 
PNPLA6 case (PT 8) showed only pyramidal signs associated with cerebellar 
ataxia, with normal cognitive and visual functions. In all three cases, and also in 
the affected brother of PT 7, a downbeat nystagmus was evident. 
The phenotype of RNF216-mediated neurodegeneration initially associated with 
Gordon Holmes syndrome, have recently been expanded to include Huntington- 
like disorder with prominent chorea, behavioral problems, severe dementia and 
low gonadotropin serum levels (Santens et al., 2015). Also, in our RNF216 case 
(PT 13) pyramidal signs were associated with hyperkinetic choreiform 
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movements, and mild cognitive impairment. A re-evaluation of the patients 
revealed reduced values of FSH and LH, with normal values of estradiol, 
progesterone, and prolactin. 
We recognized two SYNE1 cases (PT 9, 10). In one patient clinical picture is that 
of an adult-onset cerebellar ataxia with slight cerebellar atrophy at MRI, 
associated with a sensory peripheral neuropathy (PT 9). In the second case (PT 
10) a mild cerebellar ataxia with prominent dysarthria and slight pyramidal signs 
was associated with a hypergonadotropin hypogonadism. Brain MRI showed 
marked cerebellar atrophy (Figure 10). She had an affected brother with early- 
onset syndrome characterized by a moderate intellectual disability, mild cerebellar 
ataxia and normogonadotropin hypogonadism. These data confirm that recessive 
ataxia due to SYNE1 mutations is characterized by a phenotype variability from a 
slowly progressive, relatively pure cerebellar ataxia with only mild and infrequent 
extra-cerebellar symptoms starting in adult age, to a severe multisystemic 
neurodegenerative syndrome, also including intellectual disability (Synofzik et al., 
2015). This is the first report of hypogonadism associated with SYNE1 mutations. 
Two cases of Ataxia with Oculomotor Apraxia 2 (AOA2) due to mutations in 
SETX gene were detected in our cohort (PT 11 and 12). In both patients 
oculomotor apraxia was absent, but strabismus and peripheral neuropathy was 
evident in the first (PT 11). The second case (PT 12) was not suspected for AOA2 
because of clinical picture was characterized by prominent tremor and 
hyperkinetic choreiform movements without peripheral neuropathy. Furthermore, 
a family history positive for tremor was evident in father and a sister. 
A complicated neurodegenerative syndrome was present in PT 14, positive for 
compound heterozygous mutations in ZFYVE26, associated to spastic paraplegia 
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15 (SPG15). Clinical phenotype was characterized by spastic ataxia with age at 
onset at 30 years, and progressive development of extrapyramidal signs, executive 
and psychiatric signs with hallucinations and marked dysphagia requiring a 
percutaneous endoscopic gastrostomy. Typical thin corpus callosum (TCC) and 
periventricular white matter abnormalities were not present at MRI. However, the 
occurrence of TCC and white matter abnormalities is variable in SPG15 (Hanein 
et al., 2008; Boukhris et al., 2008). 
The ANO10 case (PT 15) was a Romanian patient with progressive spastic-ataxia 
syndrome with onset at 30 years of age. At 31 years she developed retrobulbar 
optic neuritis leading to the diagnosis of multiple sclerosis, confirmed by the 
presence of oligoclonal bands in cerebrospinal fluid and white matter alteration at 
MRI. We decide however to include the patient in our study because of a marked 
cerebellar atrophy at MRI (Figure 11). 
Two brothers with mild intellectual disability, strabismus and congenital non- 
progressive ataxia with marked cerebellar hypoplasia (proband PT 16) showed 
compound heterozygous mutations in PMM2, the most frequent gene associated 
with Congenital Disorder of Glycosylation (CDG Ia). The phenotype of CDG Ia 
varies from very severe to mild. Neurological symptoms include cerebellar ataxia, 
intellectual disability, retinitis pigmentosa and peripheral neuropathy. However, 
mild neurological presentations have also been reported (Drouin-Garraud et al., 
2001). 
In a patient with cerebellar ataxia associated to myoclonus, mild cognitive 
impairment and pyramidal signs (PT 17) we detected compound heterozygous 
mutations in ATP13A2 gene. Disease onset was in the fourth decade. No 
extrapyramidal signs or vertical gaze palsy were present. Molecular defects in this 
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gene have been causally associated with Kufor-Rakeb syndrome, an autosomal 
recessive form of juvenile-onset parkinsonism, and neuronal ceroid lipofuscinosis, 
a neurodegenerative disorder characterized by the intracellular accumulation of 
autofluorescent lipopigments. Recently mutations in this gene has been associated 
to a hereditary complicated spastic paraplegia (SPG78), presenting as adult-onset 
combined pyramidal-cerebellar syndrome complicated by cognitive impairment, 
axonal motor and sensory polyneuropathy, and a marked cerebellar atrophy at 
MRI (Estrada-Cuzcano et al., 2017). 
Only one case with autosomal dominant mode of inheritance was successfully 
solved, recognized as SCA35 (c.1953_1955dupACA, p.Q652dup) (PT 18). 
Clinical phenotype is characterized by an adult-onset ataxia associated with 
pyramidal signs, hyperkinetic choreiform movements, mild cognitive impairment, 
and anorexia. SCA35 was first described in Chinese families as a slowly 
progressive ataxia associated to hyperreflexia, tremor, sometimes dystonia and 
cognitive impairment. Recently SCA35 has been described also in few European 
cases. In particular in a European patient with ataxia associated with myoclonus 
has been detected a TGM6 mutation c.1951_1952insAAC that showed the same 
effect on the protein transglutaminase 6 (p.Q652dup) of our mutation (Tripathy et 
al., 2017). 
 
 
Patients with variants of uncertain significance (table 3) 
 
A homozygous mutation in RNF170 gene was detected in a patient (PT 19). This 
gene has been associated with autosomal dominant sensory ataxia 1 (SNAX1) that 
results in a progressive ataxia caused by degeneration of the posterior columns of 
the spinal cord, without cerebellar involvement. Clinical features of our patient (a 
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congenital non-progressive mild cerebellar ataxia with evident cerebellar atrophy 
at MRI, mental retardation and strabismus) was discordant to the RNF170 
phenotype. 
A young woman with congenital downbeat nystagmus, primary amenorrhea for 
ovarian failure, and tremor with onset at 18 years of age was evaluated for a very 
mild non-progressive ataxic disturbance (PT 20). She had a sister with the same 
clinical picture. Compound heterozygous mutations in AARS2 (alanyltRNA 
synthetase 2) gene was detected. Mutations in this gene were associated with a 
LeuKoENcephalopathy Progressive with ovarian failure (LKENP) in females, a 
clinical presentation previously described as ovarioleukodystrophy (Schiffmann et 
al., 1997). Neurological phenotype was characterized by progressive ataxia and 
cognitive/behavioral impairment, although in few cases no motor dysfunctions or 
only postural tremor have been reported (Dallabona et al., 2014). Congenital 
nystagmus, tremor and ovarian failure fit well to the AARS2 mutations, whereas 
the absence of leukoencephalopathy at MRI and normal cognitive function do not. 
In the same patient we also detected a single mutation in SYNE1 and in ZFYVE26 
gene, genes associated to autosomal recessive disorders, and in ABCB7 gene, 
associated to X-linked sideroblastic anemia and ataxia (Shimada et al., 1998). 
Three mutations in HARS (histidyil-tRNA synthetase) gene were detected in a 
patient with very early onset of psychomotor delay and slow progression of ataxic 
syndrome (PT 21). Severe mental delay, strabismus, microcephaly, short stature, 
ligamentous laxity completed the clinical phenotype. Cerebral MRI was normal. 
She had a sister with same clinical features. Heterozygous mutations in HARS 
gene have been associated with autosomal dominant inherited peripheral 
neuropathy (Charcot-Marie-Tooth disease, axonal, type 2W) (Safka Brozkova et 
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al., 2015). The Usher syndrome Type IIIB, an autosomal recessive disorder 
characterized by deafness and blindness, is, instead, associated with compound 
heterozygous or homozygous mutation in HARS gene (Puffenberger et al., 2012). 
The discordance of the clinical picture led us to consider the pathogenicity of 
these mutations uncertain. Single mutation in CLP1, associated with the 
autosomal recessive Pontocerebellar hypoplasia, type 10 (Karaka et al., 2014) 
have been also detected in this proband. 
Compound heterozygous mutations in HSD17B4 gene was detected in a patient 
with ataxia associated with pyramidal signs and demyelinating sensorimotor 
neuropathy with onset at 18 years old (PT 22). The HSD17B4 product, D- 
bifunctional protein (DBP), multifunctional enzyme of the peroxisomal ß- 
oxidation of fatty acids, consisting of three domain: dehydrogenase, hydratase and 
sterol carrier protein-2. Mutations were found in the dehydrogenase as well as in 
the hydratase domain; no mutations were observed yet in the sterol carrier protein- 
2 domain. Patients with DBP deﬁciency die mostly in their ﬁrst year of life. 
Typical clinical observations are hypotonia, facial dysmorphism, psychomotor 
delay, neonatal seizures, neuronal migration defects or demyelination. 
Biochemical ﬁndings are highly elevated levels of very long chain fatty acids 
(VLCFA) in plasma (Möller et al., 2001). Few cases of slowly progressive DBP 
deficiency has been described, characterized by juvenile onset of cerebellar ataxia, 
peripheral neuropathy, pyramidal signs and deafness. Blood level of VLCFA, 
pristanic acid and phytanic acid were often normal (Matsukawa et al., 2017). 
Furthermore, HSD17B4 gene has been associated to Perrault syndrome, a disorder 
characterized by sensorineural deafness and ovarian dysgenesis in females. 
Cerebellar ataxia, mental delay and peripheral neuropathy are often associated
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(Pierce at al., 2010). Clinical picture of our case was not suggestive, first of all for 
the normal auditory function. Furthermore, one mutation of our patient 
(c.727G>T; p.V243L) affected the dehydrogenase domain; the second one 
(c.2191C>T p.Q731*) occurred within the sterol carrier protein-2 domain, 
strongly suggesting that is a polymorphism. 
A mutation in CAMTA1 gene, associated to Cerebellar Ataxia, Non Progressive, 
with Mental Retardation (CANPMR), an autosomal dominant 
neurodevelopmental disorder characterized by mild mental retardation and early 
onset ataxia (Thevenon et al., 2012), has been identified in a case of our cohort 
(PT 23). Clinical phenotype of our patient was not matching because of a mild 
slight progressive adult-onset ataxia without cognitive impairment, associated 
with chronic coughing and a probable recessive inheritance. A similar reasoning 
can be applied for the mutation detected in the same patient in IFRD1 gene, 
associated to Spinocerebellar ataxia 18 (SCA18) (Brkanac et al., 2009). Apart 
from the dubious autosomal dominant pattern of inheritance, clinical picture of 
SCA18 is characterized by ataxia associated with a sensorimotor peripheral 
neuropathy. Nerve conduction studies of the proband and his sister were normal. 
Single mutations in autosomal recessive disease-associated genes (WFS1 and 
PNPLA6) have been also detected in the same proband. 
In a patient with very mild ataxia with prominent cerebellar dysarthria and onset 
in the fourth decade (PT 24) we detected heterozygous mutations in five genes: 
AFG3L2, ITPR1, SPAST, ABHD12, and NOL3. Heterozygous mutations in 
AFG3L2 gene have been associated to Spinocerebellar ataxia type 28 (SCA28) 
(Cagnoli et al., 2010) whereas heterozygous mutations in ITPR1 gene have been 
associated to Spinocerebellar ataxia type 29 (SCA29) (Synofzik et al., 2011), both
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adult-onset autosomal dominant spinocerebellar ataxia slowly progressive. Nerve 
conduction studies were usually normal in both SCAs, as in our patient. Further 
analysis of segregation are needed to recognize the value of these mutations. 
SPAST gene is associated to the most frequent autosomal dominant form  of 
spastic paraplegia (SPG4). The absence of pyramidal signs in the patient, strongly 
suggest that this variant is a polymorphism. The autosomal recessive disorder 
Polyneuropathy, Hearing loss, Ataxia, Retinitis pigmentosa, and Cataract 
(PHARC) caused by mutations in ABHD12 gene (Fiskerstrand et al., 2010), is not 
suggestive for clinical phenotype and pattern of inheritance. Autosomal dominant 
Familial Cortical Myoclonus due to mutations in NOL3 gene (Russell et al., 2012) 
is characterized by a clinical picture more complicated than that of our case. 
In a complicated case of cerebellar ataxia, associated with myoclonus, an episode 
of generalized seizure, neurosensorial hypoacusia, cataract, neurogenic bladder, 
dolichocolon and rectal atony, we detected two missense mutations in PLA2G6 
gene, and heterozygous mutations in SLC9A1 and DNMT1 genes. PLA2G6- 
associated neurodegeneration (PLAN) (Kurian et al., 2008) comprises a 
continuum of three autosomal recessive phenotypes: Infantile Neuroaxonal 
Dystrophy, characterized by very early onset and progressive form of 
psychomotor regression or delay, and spastic tetraparesis; Atypical Neuroaxonal 
Dystrophy, associated to childhood till second decade onset of ataxia and 
neuropsychiatric disorders; and PLA2G6-related dystonia-parkinsonism with 
variable age of onset of dystonia, parkinsonism and neuropsychiatric changes and 
often cognitive decline (Gregory et al., 2008). Clinical phenotype of our patient 
was not congruous to PLA2G6-associated disorders, raising doubts about the 
value of the mutations found. In the same patient we also detected a heterozygous
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mutation of SLC9A1 gene, associated to the autosomal recessive Lichtenstein- 
Knorr syndrome. Clinical features of the syndrome comprise severe progressive 
sensorineural hearing loss and cerebellar ataxia with onset in childhood or young 
adulthood (Guissart et al., 2015). Auditory impairment is part of clinical features 
of the Autosomal Dominant Cerebellar Ataxia, Deafness, and Narcolepsy 
(ADCADN), due to mutation in DNMT1, characterized by adult onset progressive 
cerebellar ataxia, narcolepsy/cataplexy, sensorineural deafness and dementia. 
Despite the presence of ataxia and hypoacusia in our patient, the presence of 
seizure, myoclonus and intestinal dysfunction are not part of the clinical 
phenotype of both Lichtenstein-Knorr syndrome and ADCADN. 
A patient with ataxia associated with oculomotor apraxia, diplopia and mild 
pyramidal signs (PT 26) presented compound heterozygous mutations in both 
SACS gene and in SYNE1 gene, and a heterozygous mutation in CACNA1G gene. 
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS), caused 
by compound heterozygous or homozygous mutations in SACS gene, is clinically 
characterized by an early onset spastic ataxia with a sensorimotor peripheral 
neuropathy (Bouchard et al., 1978). Retinal striation, mental delay, progressive 
myoclonic epilepsy and skeletal abnormalities have been also described as cases 
with absent pyramidal involvement or absent peripheral neuropathy (Ogawa et al., 
2004; Muona et al., 2015; Armour et al., 2016). SYNE1 gene was initially defined 
as a pure cerebellar ataxia, then recognized as associated to involvement of first 
and second motor neuron and cognitive delay/impairment. Clinical features of our 
patient could not be clearly associated with either SACS or SYNE1 gene, in 
particular for the oculomotor apraxia that is a predominant feature. Autosomal 
dominant Spinocerebellar ataxia type 42 (SCA42) due to mutation in CACNA1G
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gene, is a slowly progressive pure cerebellar ataxia, sometimes associated with 
pyramidal tract involvement. Few families have been described at the moment 
only with the same R2715H mutation (Coutelier et al., 2015; Morino et al., 2015). 
Clinical features of our patient and absent positive familial history make the 
pathogenicity of our mutation unlikely. 
In a young woman (PT 27) with ataxia associated with mild pyramidal signs, and 
a congenital strabismus, we detected a heterozygous mutation in CACNA1A gene, 
found to be responsible for three disorders with autosomal dominant inheritance: 
Episodic Ataxia type 2 (EA2), Familial Hemiplegic Migraine type 1 (FHM1), and 
Spinocerebellar ataxia 6 (SCA6). EA2 is mainly characterized by episodes of 
ataxia, vertigo, and nausea lasting for minutes to hours, often associated with 
progressive ataxia, and clinical overlap with FHM1 and SCA6 have been 
described (Romaniello et al., 2010). The same patient presented a heterozygous 
mutation also in SPTBN2 gene. Heterozygous missense or in-frame mutations in 
SPTBN2 cause autosomal dominant Spinocerebellar ataxia 5 (SCA5), in contrast, 
stop codon homozygous or compound heterozygous mutations are responsible of 
the Spinocerebellar ataxia 14, autosomal recessive (SCAR14). De novo mutations 
in SPTBN2 have also been detected in congenital form of ataxia (Parolin 
Schnekenberg et al., 2015). SCA5 is a relatively pure cerebellar ataxia with onset 
generally in the third or fourth decade of life. SCAR14 is characterized by a 
congenital ataxia and cognitive impairment with additional mild spasticity 
(Elsayed et al., 2014). Also a single mutation in SYNE1 has been identified in the 
proband. 
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DISCUSSION 
 
Single Gene Standard Sequencing in disorders with high genetic heterogeneity, 
such as hereditary ataxias, has a low diagnostic yield per gene. After exclusion of 
repeat expansion ataxias, as SCAs for autosomal dominant forms, and Friedreich 
ataxia for recessive ones, over 80 other genes associated with various forms of 
ataxia remain candidates. Furthermore, since 2010 the use of NGS techniques has 
increased the number of new genes associated to ataxias, and clinical phenotypes 
of old genes has been expanded. We used a Targeted Next-Generation 
Resequencing Panel containing 273 genes, known or supposed to be related to 
hereditary ataxias, as a tool to investigate 39 heterogeneous patients with ataxia 
without a molecular diagnosis. Our cohort was largely non-consecutive and most 
patients had already been investigated for different genes based on clinical 
features. The selected patients had a clinical suspicion of a genetic etiology, based 
on the combination of cerebellar ataxia phenotype plus either an age at onset 
below 45 years or a positive family history. Patients with congenital ataxias were 
also included. Most patients of our cohort had a complex phenotype, in which 
ataxia was associated with neurological and extraneurological features. 
The diagnostic yield of our study (46%) is highest than those obtained in previous 
TRP ataxia studies, which had an average diagnostic rate of 17%, and also than of 
ES studies that reached a 36% of diagnostic yield. This positive result surely 
depends on the significantly higher number of genes selected in our panel (273 
genes) respect to the mean of 88 genes (range 42-159) of the other previous ataxia 
panels. A key role has also been played by the efficient clinical assessment of the 
patients, necessary for the confirmation of the pathogenicity of the different
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variants detected. The presence of a positive family history remained the most 
important isolated feature associated with the finding of a pathogenic mutation. In 
particular seven out of eight patients with known consanguineous parents reached 
a positive result. 
The most frequent gene detected in our cohort was SPG7 confirming the 
important causative role of this gene in undiagnosed ataxias (Pfeffer et al., 2015). 
However, noteworthy is the fact that in two of these patients (PT 3 and 4), during 
the study process we identified the same mutations in SPG7 gene through Single 
Gene Testing, just for the growing evidence in literature of the role of this gene in 
ataxias associated also with mild pyramidal signs, such as in our patients. 
Next in frequency was PNPLA6 gene, not commonly detected in other ataxic 
cohorts of previous TRP or ES studies. This result depends on the fact that in our 
cohort six out of 39 cases (15%) presented a hypogonadism, and the "new genes" 
associated with hypogonadism (RNF216, OTUD4, STUB1, and PNPLA6) had not 
previously been investigated in our patients because of lack of availability of 
genetic testing. However, one of the PNPLA6 patients (PT 8) had not 
hypogonadism, and also the patient detected with compound heterozygous 
mutations in RNF216 gene (PT 13) was not identified as hypogonadic, and only a 
re-evaluation of the case showed low FSH and LH levels with normal estradiol, 
progesterone and prolactin levels. In one patient with hypogonadotropic 
hypogonadism (PT 2) the diagnosis was SPG7, and in one case with 
hypergonadotropic hypogonadism and a positive family history for hypogonadism 
in a brother (PT 10), the gene detected was surprisingly SYNE1. This 
endocrinological finding has never been associated to SYNE1 gene, expanding the 
phenotype of the disease. 
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The clinical phenotype of our RNF216 patient characterized by hyperkinetic 
choreiform movements confirms the precedent description of a Huntington-like 
disorder associated with this gene (Santens et al., 2015). 
Lastly, in one woman with ovarian failure (PT 20) possible pathogenic variants 
were detected in AARS2 gene, associated with Leukoencephalopathy progressive 
with ovarian failure, and in a young man with hypergonadotropic hypogonadism 
(PT 33), variants with unlikely pathogenicity were identified. 
Mutations in SYNE1 and in SETX genes has been identified in two probands each. 
These genes have frequently been detected in previous TRP and ES ataxia studies 
too (Nemeth et al., 2013; Mallaret et al., 2016; Sawyer et al., 2014; Fogel et al., 
2014; Marelli et al., 2016), because few families have been screened for SYNE1 
gene as the gene is very large, and SETX gene is not routinely tested in UK and 
France whereas in our probands clinical features were atypical. 
Mutations in SACS gene, responsible for ARSACS, have been frequently detected 
in other TRP and ES studies (Nemeth et al., 2013; Mallaret et al., 2016; 
Hadjivassiliou et al., 2016; Iqbal et al., 2017; Sawyer et al., 2014; Pyle et al., 
2015). In our cohort none has been recognized as ARSACS, probably because in a 
previous study we tested for SACS gene a cohort of ARSACS-like patients from 
our Ataxias Clinic (Criscuolo et al., 2004). 
In nine patients (23%) we found possible pathogenic variants of uncertain 
significance, pointing to the difficulty of the determination of the pathogenicity of 
a given variant, and to the necessity of further testing and family studies for 
validation or exclusion of genetic findings. However, the sharing of VOUS and 
clinical phenotypes will allow a possible future validation of the pathogenicity of 
variants. 
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Finally, in 31% of cases no candidate variants or variants with unlikely 
pathogenicity were identified. Possible reasons include the presence of cases in 
which causal variants are present in novel genes that are yet to be identified or 
were found during the study period. Such newly identified genes can be added 
into TRP on a regular basis. Furthermore, some disease-causing variants might be 
localized in the promotor, introns, or other non-coding DNA or could be indels or 
copy number variations that are not analyzed in our study. 
The patients in which we could not detect confirmed pathogenic variants are 
candidates for exome sequencing studies. 
 
 
CONCLUSION 
 
The clinical use of NGS techniques is becoming more widespread; our findings 
suggest that after exclusion of repeat expansion ataxias, ataxia TRP, eventually 
followed by full exome analyses if first approach was negative, could be a good 
first tier diagnostic line, when a specific single gene is not immediately suspected 
to be causative. Our TRP provides high-quality sequencing data with excellent 
coverage of the selected genes and a very high diagnostic yield. 
38 
 
TABLES AND FIGURES 
 
 
 
Table 1. List of the 273 genes included in the ataxia panel 
 
 
GENES MIM GENES MIM GENES MIM GENES MIM 
AARS2 612035 C12ORF65 613541 DKC1 300126 GRM1 604473 
ABCB7 300135 C9ORF72 614260 DNAJC19 608977 HARS 142810 
ABCD1 300371 CA8 114815 DNAJC3 601184 HARS2 600783 
ABHD12 613599 CACNA1A 601011 DNMT1 126375 HEXA 606869 
ACO2 100850 CACNA1G 604065 EEF2 130610 HEXB 606873 
ADCK3 606980 CACNB4 601949 EIF2B1 606686 HIBCH 610690 
ADGRG1 604110 CAMTA1 611501 EIF2B2 606454 HSD17B4 601860 
AFG3L2 604581 CASK 300172 EIF2B3 606273 INPP5E 613037 
AHDC1 615790 CC2D2A 612013 EIF2B4 606687 ITPR1 147265 
AHI1 608894 CCDC88C 611204 EIF2B5 603945 KCNA1 176260 
ALDH5A1 610045 CD40LG 300386 ELOVL4 605512 KCNA2 176262 
ALG3 608750 CDK5 123831 ELOVL5 611805 KCNC1 176258 
ALG6 604566 CEP104 616690 ERCC4 133520 KCNC3 176264 
AMACR 604489 CEP290 610142 ERCC8 609412 KCND3 605411 
AMPD2 102771 CEP41 610523 EXOSC3 606489 KCNJ10 602208 
ANO10 613726 CHMP1A 164010 EXOSC8 606019 KCTD7 611725 
APOB 107730 CLCN2 600570 FA2H 611026 KIF1A 601255 
APTX 606350 CLN5 608102 FARS2 611592 KIF1C 603060 
ARL13B 608992 CLN6 606725 FASTKD2 612322 KIF7 611254 
ARSA 607574 CLN8 607837 FGF14 601515 LAMA1 150320 
ATCAY 608179 CLP1 608757 FLVCR1 609144 LMNB2 150341 
ATG5 604261 COA7 615623 FMR1 309550 LYST 606897 
ATL1 606439 COQ2 609825 FOLR1 136430 MARS2 609728 
ATM 607585 COQ4 612898 FXN 606829 MED17 603810 
ATP13A2 610513 COQ9 612837 GALC 606890 MFN2 608507 
ATP1A3 182350 SPP1 166490 GAN 605379 MFSD8 611124 
ATP2B3 300014 CSTB 601145 GBA2 609471 MKS1 609883 
ATP7B 606882 CTBP1 602618 GBE1 607839 MMACHC 609831 
ATP8A2 605870 CTSD 116840 GDAP1 606598 MME 120520 
BEAN1 612051 CWF19L1 616120 GFAP 137780 MRE11A 600814 
BRAT1 614506 CYP27A1 606530 GJB1 304040 MTPAP 613669 
BRF1 604902 CYP7B1 603711 GJC2 608803 MTTP 590075 
C10ORF2 606075 DARS 603084 GLB1 611458 MVK 251170 
C12ORF65 613541 DARS2 610956 GOSR2 604027 NAGLU 609701 
C5ORF42 614571 DDHD2 615003 GRID2 602368 NDUFS1 157655 
39 
 
GENES MIM GENES MIM GENES MIM GENES MIM 
NDUFS7 601825 POLR3A 614258 SLC2A1 138140 TMEM237 614423 
NEU1 608272 POLR3B 614366 SLC33A1 603690 TMEM240 616101 
NOL3 605235 PPT1 600722 SLC35A2 314375 TMEM67 609884 
NOP56 614154 PRICKLE1 608500 SLC52A2 607882 TOP1 126420 
NPC1 607623 PRKCG 176980 SLC6A19 608893 TPP1 607998 
NPC2 601015 PRNP 176640 SLC9A1 107310 TRNT1 612907 
NPHP1 607100 PRPS1 311850 SLC9A6 300231 TRPC3 602345 
OFD1 300170 PRRT2 614386 SMPD1 607608 TSEN2 608753 
OPA1 605290 PSAP 176801 SNAP25 600322 TSEN34 608754 
OPA3 606580 PSEN1 104311 SNX14 616105 TSEN54 608755 
OPHN1 300127 PTF1A 607194 SPAST 604277 TTBK2 611695 
OTUD4 611744 PTRH2 608625 SPG11 610844 TTC19 613814 
PAX6 607108 QARS 603727 SPG7 602783 TTC21B 612014 
PDE6D 602676 RAB3GAP1 602536 SPTBN2 604985 TTPA 600415 
PDHA1 300502 RARS 107820 SRD5A3 611715 TUBB3 602661 
PDSS1 607429 RARS2 611524 STS 300747 TUBB4A 602662 
PDSS2 610564 RELN 600514 STUB1 607207 UBA5 610552 
PDYN 131340 RNF170 614649 STXBP1 602926 UBR4 609890 
PEX10 602859 RNF216 609948 SURF1 185620 UCHL1 191342 
PEX16 603360 RPGRIP1L 610937 SYNE1 608441 VAMP1 185880 
PEX2 170993 RUBCN 613516 SYNE2 608442 VARS2 612802 
PEX6 601498 SACS 604490 SYT14 610949 VLDLR 192977 
PEX7 601757 SAMD9L 611170 TBC1D23 617687 VRK1 602168 
PHYH 602026 SCN1A 182389 TCTN1 609863 VWA3B 614884 
PIK3R5 611317 SCN2A 182390 TCTN2 613846 WDR81 614218 
PLA2G6 603604 SCN8A 600702 TCTN3 613847 WFS1 606201 
PLEKHG4 609526 SCYL1 607982 TDP1 607198 WWOX 605131 
PLP1 300401 SEPSECS 613009 TGM6 613900 XPA 611153 
PMM2 601785 SETX 608465 THG1L Nd XRCC4 194363 
PMPCA 613036 SIL1 608005 TINF2 604319 ZFYVE26 612012 
PNKP 605610 SLC17A5 604322 TMEM138 614459 ZFYVE27 610243 
PNPLA6 603197 SLC1A3 600111 TMEM216 613277 ZNF423 604557 
POLG 174763 SLC25A46 610826 TMEM231 614949 ZNF592 613624 
  
 
Table 2. Clinical features and genetic results of patients with confirmed pathogenic variants 
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Table 3. Clinical features and genetic results of patients with VOUS 
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Table 4. Clinical features and genetic results of patients with variants with unlikely pathogenicity or no candidate variants 
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Table 5. Sexual assessment in patients with PNPLA6 mutations 
 
 
 
 PT 6 PT 7 PT 7 brother 
LH 
mU/ml (nv 5-18) 
0.1 10 3.2 
FSH 
mU/ml (nv 5-18) 
0.1 7.4 5.9 
Testosteron 
ng/dl (nv 300-900) 
35 182 256 
Androstenedion 
ng/ml (nv 1.1-3.5) 
0.88 1.85 1.81 
DHEA-S 
μg/dl (nv 80-560) 
148 173 308 
17 β Estradiol 
pg/ml (nv 0-56) 
59.9 35.4 not done 
17 OH Progesteron 
ng/ml (nv 0.6-3.3) 
0.71 0.08 0.76 
Testicular 
echography 
4 ml (each) Left hypotrophic 
undescended 
testis, reduced 
volume of the 
right testis 
Reduced volume 
of both testes 
 
 
 
 
Figure 1. Cost per genome since 2001 (courtesy of www.genome.gov) 
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Figure 2. The large increase of published NGS reports in biomedical domain 
since 2008 (Chaitankar et al., 2016) 
 
 
 
 
 
 
Figure 3. Diagnostic yield in literature hereditary ataxias patients cohorts 
(Galatolo et al., 2017) 
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Figure 4. Workflow of SureSelect Target Enrichment system for library 
preparation (Image courtesy of www.agilent.com) 
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Figure 5. Bridge amplification and cluster generation for Illumina sequencing 
(Image courtesy of www.illumina.com) 
 
 
 
 
1. Prepare Genomic DNA Sample: randomly fragment genomic DNA and ligate adapters 
to both ends of the fragments. 2. Attach DNA to Surface: bind single-stranded fragments 
randomly to the inside surface of the flow cell channels. 3. Bridge Amplification: add 
unlabeled nucleotides and enzyme to initiate solid-phase bridge amplification. 4. 
Fragments Become Double Stranded: the enzyme incorporates nucleotides to build 
double-stranded bridges on the solid-phase substrate. 5. Denature the Double-Standed 
Molecules: denaturation leaves single-stranded templates anchored to the substrate. 6. 
Complete Amplification: several million dense clusters of double-stranded DNA are 
generated in each channel of the flow cell. 
50  
Figure 6. Sequencing and base calling for Illumina sequencing (Ansorge, 2009) 
 
 
Amplified DNA fragments are subjected to sequencing-by-synthesis using 3' blocked 
labelled nucleotides: extend first base, read, and deblock; repeat step above to extend 
strand; generate base calls. 
 
 
 
 
Figure 7. Chart reporting sequencing quality. An average of 99% target regions 
were sequenced almost 50 times (50X), 96% 100X and 82% 200X 
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Figure 8. Brain MRI of patient 2 carrying mutations in SPG7 gene. 
T2-weighted sagittal and axial brain MRI showing cerebellar atrophy 
 
 
 
 
 
 
Figure 9. Brain MRI of patient 6 carrying mutations in PNPLA6 gene. 
T2-weighted sagittal and axial brain MRI showing marked cerebellar atrophy 
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Figure 10. Brain MRI of patient 10 carrying mutations in SYNE1 gene. 
T2-weighted sagittal and axial brain MRI showing marked cerebellar atrophy 
 
 
 
 
 
 
Figure 11. Brain MRI of patient 15 carrying mutations in ANO10 gene. 
T2-weighted sagittal brain MRI showing marked cerebellar atrophy and FLAIR 
axial brain MRI showing white matter abnormalities. 
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